Understand the source comparison
PE-22-28 Dosage Antidepressant 2026: Clinical Context vs Compound Availability Comparison
PE-22-28 Research peptide only. No FDA approval No Phase I trials published; rodent doses 0.5–5 mg/kg Available through research suppliers; not for human use IRAP inhibition → increased BDNF, hippocampal neurogenesis Promising preclinical neurogenesis data, bu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PE-22-28
- Research peptide only. No FDA approval
- No Phase I trials published; rodent doses 0.5–5 mg/kg
- Available through research suppliers; not for human use
- IRAP inhibition → increased BDNF, hippocampal neurogenesis
- Promising preclinical neurogenesis data, but entirely speculative for human antidepressant dosing in 2026. No safety or efficacy trials exist
- SSRIs (e.g., sertraline)
- FDA-approved
- Established: 50–200 mg/day oral
- Widely available via prescription
- Serotonin reuptake inhibition
- Gold-standard first-line treatment with decades of human data
- Ketamine (esketamine)
- FDA-approved for TRD
- Established: 56–84 mg intranasal twice weekly
- Available via certified clinics (REMS program)
- NMDA receptor antagonism → rapid synaptogenesis
- Rapid-acting option for treatment-resistant depression with strict monitoring requirements
- Semax
- Not FDA-approved (approved in Russia)
- Human trials: 300–600 mcg intranasal daily
- Research suppliers only
- Melanocortin receptor modulation
- Cognitive enhancement data in humans; limited depression-specific trials
- BPC-157
- Research peptide only
- Rodent doses 10 mcg/kg–10 mg/kg; no validated human dosing
- Multiple proposed pathways including angiogenesis, neuroprotection
- Widely used in peptide research communities but lacks controlled human trials for any indication
- The table underscores a pattern across novel peptides: availability through research suppliers does not equate to therapeutic readiness. PE-22-28's position in 2026 mirrors BPC-157 or P21. Accessible for in vitro or animal research, but without the clinical trial infrastructure that would make dosing recommendations scientifically defensible.